Matthew Eaton’s Post

How AI and machine learning can help the healthcare industry advance. “I think the driving future in biotech, specifically where AI is involved, is in the generation and curation of datasets that can be used to train and empower all of the complex models around it. We're not really facing a bottleneck on the complexity of the models. We are facing a bottleneck in the complexity of the data and the applicability of the data to the outcomes that we want to infer through the models that we train,” said @Andrei Georgescu of Vivodyne. Big Tech is to get involved in biotech, the business models are starkly different, as was pointed out by Atomwise's Abraham Heifets. “There's a fundamental mismatch in how you ascribe value,” he said. Biotech companies focus on developing drugs using platform technologies that tend to become commoditized quickly, making it a challenge for them to maintain a competitive advantage for long periods. In contrast, tech companies leverage platform technologies with network effects that allow them to maintain dominance for decades. Novartis,Isomorphic Labs, Eli Lilly and Company,Informa Connect, Abraham Heifets, ArrePath,Chris Benko, Susan Kirsh MD MPH, Ian Kerwin #BiotechShowcase #healthcare #ai

I have known Harry Glorikian for a long time, since my Genoptix, Inc. and Novartis days. We have gone through the journey of adoption of #precisionmedicine #precisiononcology. This interview was very special to me. Chatting with an old friend, we covered a variety of topics: 🔥 How generative AI can help accelerate bring new medicines to patients. 🔥Share our generative AI journey as a leader in this space Huma.AI. What worked and what didn't. 🔥What does the future hold with this transforming technology? #generativeai #lifesciences #drugdevelopment

What role does unlearning have in utilizing AI tools? Unlearning may be an odd word to some people. Although it is in the dictionary, it sounds like a made-up word. To quote the definition of unlearning from The Cambridge Dictionary, unlearning is “to make an effort to forget your usual way of doing something so that you can learn a new and sometimes better way”. This is starting to sound positively dangerous. Why would we try and forget an experience that is useful to us and can guide future processes? However, once we start embracing radically different new technologies, trying to bend the old ways to the new may slow us down in figuring out a new way of working and result in a suboptimal end process. This is where the concept of unlearning starts looking more attractive. If we have an old process in the back of our mind, can we truly say we are engaging in sufficient ‘blue-sky thinking’ to come up with something radically different? It may be difficult for us to apply this concept in the world of pharmaceuticals, given the well-established rules and regulations. However, is it time to start asking ourselves how we can accelerate change using powerful principles like unlearning and AI? #AI #innovation #pharmaceuticals #SLR #literature

🔥🎙️ The Future of Drug Discovery Meets AI: A Must-Listen! 🎙️🔥 🚀 Did you know? In less than a year, generative AI models like GPT-4 have started to redefine how we manage information, offering unparalleled accuracy, speed, and innovation. But what does this mean for the world of drug discovery, development, and healthcare? 🔍 The Challenge: Many professionals in the biopharma sector might be unaware of the seismic shifts on the horizon. The direct application of these powerful AI models to biopharma data can be risky. Issues like the "hallucination problem" can trip them up. 🌟 Enter Lana Feng, Ph.D. CEO and co-founder of Huma.AI In a riveting episode of The Harry Glorikian Show, Lana sheds light on how Huma.ai is collaborating with OpenAI to tailor GPT-4 for the biotech and pharmaceutical landscape. Their goal? Making AI more private, secure, reliable, and transparent for drug development. 👉 Why Listen? - Understand the transformative potential of generative AI in drug discovery. - Learn about the challenges and solutions in integrating AI into biopharma. - Get insights directly from an industry leader paving the way for this integration. 🔗 Tune in to The Harry Glorikian Show to stay ahead of the curve! If you're in the life sciences industry or just curious about the future of AI in healthcare, this episode is a goldmine of insights. Don't miss out! #GenerativeAI #DrugDiscovery #Biopharma #Innovation #HarryGlorikianShow #HumaAI #FutureOfHealthcare #gpt4 OpenAI #artificialintelligence #machinelearning #largelanguagemodels

Today's #interestingread is the recent advice on 𝙎𝙪𝙘𝙘𝙚𝙨𝙨𝙛𝙪𝙡 𝙖𝙣𝙙 𝙩𝙞𝙢𝙚𝙡𝙮 𝙪𝙥𝙩𝙖𝙠𝙚 𝙤𝙛 𝙖𝙧𝙩𝙞𝙛𝙞𝙘𝙞𝙖𝙡 𝙞𝙣𝙩𝙚𝙡𝙡𝙞𝙜𝙚𝙣𝙘𝙚 𝙞𝙣 𝙨𝙘𝙞𝙚𝙣𝙘𝙚 𝙞𝙣 𝙩𝙝𝙚 𝙀𝙐. This document outlines a fairly comprehensive analysis of the current landscape of #AI adoption in science in the EU, projected risks and impact, a summary of the policy landscape, and 4 key recommendations going forward: 👉"Develop and deploy frameworks, including flexible dedicated funding mechanisms for research with AI." 👉"Improve quality standards of AI systems and provide fair access for all researchers working on and with AI research." 👉"Protect and invest into efficient concerted actions between existing research infrastructures, Euro HPC, and a future Institute for Research with AI." 👉"Ensure that AI is driven by people living in an open society. Protect researchers, individuals, and communities from being driven by AI to only generate profit or be controlled by entities while ignoring or opposing EU core values and principles." Download the whole document here 👉https://lnkd.in/ehAEfK6a #AIforGood #ArtificialIntelligence #RandD #biopharma #biomedicine

Novel AI methodologies applied to real-world data hold the key to faster and safer drug development, and understanding what aspects of data AI responds to is invaluable. This week, The Economist released their Technology Quarterly, focusing on AI and health, where they call out how, amid growing data demands in pharma, patient data privacy concerns are becoming more prominent. In the report, Natasha Loder discusses how Owkin is a pioneer in federated learning for healthcare research and drug development. We combine privacy-enhancing technologies, like federated learning, with critical clinical expertise and a network of academic researchers to break medical silos and accelerate innovation in real-world healthcare settings. Read more in her story on how artificial intelligence is taking over drug development https://lnkd.in/d-uzfPAy

🚀🏥 We are at the cusp of a transformative era in healthcare! At the #LondonBiotechnology Show 2024, Microsoft's #ThomasBalkizas unveiled how AI is poised to revolutionise the sector. From accelerating clinical trials to devising personalised medicine, AI is transforming from a helpful tool to a game-changer in healthcare. Balkizas emphasised the profound impact of Generative AI, enhancing everything from routine administrative tasks to complex clinical processes. This "tipping point" marks the dawn of a new era where AI becomes an integral part of healthcare innovation.🔗 #AI #HealthcareInnovation #Microsoft #Biotechnology #GenerativeAI #PersonalisedMedicine

Machine learning drives the development of biotech, biopharma, and safety, and these ODSC East sessions will show how to make it all happen. #DataScience #AI #ArtificialIntelligence https://hubs.li/Q02t1CQt0

"Media scare stories about AI software seizing control of humanity are currently popular, but in reality employing AI is less like building a mechanical overlord than it is like training a super-intern". Read more about how Pfizer is using AI to speed up and smarten clinical development: #AI #AIAct #Digital #pfizerproud

Artificial Intelligence has become an aid for everyone! In this article, we will explore how universities are leveraging AI, the utility and drawbacks of its use by applicants, and strategies for maintaining a healthy balance for the future. What do you think about it?